PSB-172656 is a selective MRGPRX2 antagonist with subnanomolar potency (K 0.142 nM) that blocks mast cell activation and prevents allergic reactions in mouse models.
PSB-172656 is a highly potent, selective, and metabolically stable MRGPRX2/MRGPRB2 antagonist that effectively blocks mast cell activation and prevents allergic and anaphylactic reactions in preclinical models.
Absolute Event Rate: 0% vs 0%
The MAS-related G protein-coupled receptor-X2 (MRGPRX2), an orphan receptor expressed on mast cells (MCs), is upregulated upon inflammation and induces hypersensitivity and inflammatory diseases. In contrast to the large number of MRGPRX2 agonists, only a few antagonists have been described, and no optimization has been reported to improve potency, selectivity, and drug-like properties. Antagonists with ancillary inhibition of the putative mouse ortholog MRGPRB2 have not been described. Here, we present a multi-disciplinary approach involving chemistry, biology, and computational science, resulting in the development of a small-molecule MRGPRX2 antagonist (PSB-172656, 3-ethyl-7,8-difluoro-2-isopropylbenzo4,5imidazo 1,2-a pyrimidin-4(1H)-one) based on a fragment screening hit. The compound exhibits metabolic stability, low cytotoxicity, and competitive blockade of MRGPRX2 activation induced by a diverse range of agonists. It displays subnanomolar potency in Ca mobilization assays (K value 0.142 nM) and was found to block MRGPRX2-mediated Gα and Gα dissociation, in addition to β-arrestin-2 recruitment. PSB-172656 is selective for MRGPRX2 versus all other MRGPRX subtypes. Its effect on MCs was confirmed in cell lines, including rat basophilic leukemia cells (RBL-2H3) recombinantly expressing human MRGPRX2, human Laboratory of Allergic Diseases 2 (LAD2) MCs, and native human skin MCs. PSB-172656 was found to additionally block the putative mouse ortholog of MRGPRX2, MRGPRB2, as determined in Ca mobilization assays (K 0.302 nM), and to prevent mouse tracheal contractions, local allergic reactions, and systemic anaphylactic symptoms. PSB-172656 constitutes a unique pharmacological tool and has the potential to be developed as a drug for mast cell-mediated hypersensitivity reactions and chronic inflammatory diseases, addressing a huge unmet medical need.
Hamwi et al. (Mon,) reported a other. PSB-172656 is a selective MRGPRX2 antagonist with subnanomolar potency (K 0.142 nM) that blocks mast cell activation and prevents allergic reactions in mouse models.